FDG PET/CT as a prognostic biomarker in the era of molecular-targeting therapies: max SUVmax predicts survival of patients with advanced renal cell carcinoma

• Published in: BMC cancer Vol. 16; no. 1; p. 67
• Main Authors: Nakaigawa, Noboru, Kondo, Keiichi, Tateishi, Ukihide, Minamimoto, Ryogo, Kaneta, Tomohiro, Namura, Kazuhiro, Ueno, Daiki, Kobayashi, Kazuki, Kishida, Takeshi, Ikeda, Ichiro, Hasumi, Hisashi, Makiyama, Kazuhide, Kubota, Yoshinobu, Inoue, Tomio, Yao, Masahiro
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 08.02.2016; BioMed Central
• Subjects: Adult; Aged; Aged, 80 and over; Biological activity; Biological markers; Carcinoma, Renal cell; Carcinoma, Renal Cell - diagnostic imaging; Carcinoma, Renal Cell - pathology; Carcinoma, Renal Cell - surgery; Care and treatment; Complications and side effects; Development and progression; Enrollments; Female; Fluorodeoxyglucose F18 - therapeutic use; Glucose - metabolism; Humans; Kidney cancer; Male; Medical imaging; Medical prognosis; Metastasis; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Neoplasm Recurrence, Local - diagnostic imaging; Neoplasm Recurrence, Local - pathology; Neoplasm Recurrence, Local - therapy; Neoplasm Staging; Nephrectomy; Pathology; Patient outcomes; Patients; PET imaging; Positron-Emission Tomography; Prognosis; Tomography; Tomography, X-Ray Computed; Treatment Outcome; United States

Various molecular-targeting therapies have become available for the treatment of advanced renal cell carcinoma (RCC). Accurate prognostication is desirable for choosing the appropriate treatment for individual patients. (18)F-2-fluoro-2-deoxyglucose positron-emission tomography/computed tomography (...